P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
P95 BV (“P95”), a leading global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, is excited to announce the acquisition of Assign DMB. Founded by current CEO Anton Klingler in 2005, Assign DMB stands at the forefront of clinical research organisations (CROs) in Austria and is renowned for its exceptional clinical data management and biometrics services, particularly in the areas of infectious diseases and vaccines. Backed by Boston and Amsterdam-based Ampersand Capital Partners, P95 is proud to raise the bar in leading innovation and excellence in clinical research globally with this acquisition.
Thomas Verstraeten, CEO of P95 comments, “It is with great pleasure that we welcome Anton and his team to the P95 family. Assign DMB is a world class leader in the areas of data management and biostatistics. By combining forces, we further enhance our capacity to implement both clinical and non-interventional studies, with a continued focus on vaccines and infectious diseases. Like us, Assign DMB has supported studies in various regions worldwide. Our combined global expertise enables us to deliver our services at any location worldwide, including underserved and developing countries.”
Anton Klinger, CEO of Assign DMB adds, “I am delighted to join forces with P95. This acquisition is a significant milestone for Assign DMB, and I am confident that our combined expertise will enable us to deliver even greater value to our clients. Together, we will continue to strive for excellence in clinical research.”